Compare CLW & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLW | ARMP |
|---|---|---|
| Founded | 1926 | N/A |
| Country | United States | United States |
| Employees | 3710 | N/A |
| Industry | Paper | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.2M | 199.7M |
| IPO Year | 2008 | 1996 |
| Metric | CLW | ARMP |
|---|---|---|
| Price | $14.43 | $3.72 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $20.00 | $17.50 |
| AVG Volume (30 Days) | ★ 269.7K | 75.1K |
| Earning Date | 10-26-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,555,400,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.30 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.42 | N/A |
| 52 Week Low | $11.73 | $2.75 |
| 52 Week High | $23.59 | $14.98 |
| Indicator | CLW | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 39.88 | 55.78 |
| Support Level | $12.21 | $3.38 |
| Resistance Level | $14.56 | $3.96 |
| Average True Range (ATR) | 0.97 | 0.36 |
| MACD | 0.14 | 0.11 |
| Stochastic Oscillator | 43.93 | 93.64 |
Clearwater Paper Corp is engaged in the manufacturing and supplier of Solid Bleached Sulfate (SBS) paperboard packaging products. The company products includes: SBS paperboard which is a premium paperboard grade that is frequently used to produce folding cartons, food service, commercial printing items. It generates maximum revenue from Pulp and Paperboard segment. Company operate in United States and have globalized access too. Geographically, it derives maximum revenue from the United States.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.